Search

everythinglearnresearchcommunity

for

Search:↓

Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.

Calcipotriol's effectiveness for treating alopecia areata is unclear and needs more research.

Certain gut bacteria may protect against alopecia areata, while others may increase the risk.

Regenerative cellular therapies show promise for treating non-scarring hair loss but need more research.

Further research is needed to understand how the microbiome affects hair loss in Alopecia Areata.

COVID-19 may harm male reproductive health and lower testosterone levels, potentially affecting fertility and causing erectile dysfunction. More research is needed.

Teledermatology is highly effective for diagnosing and managing hair loss.

The most common cause of hair loss in children is tinea capitis, followed by alopecia areata and telogen effluvium.

Blocking IL-12/IL-23p40 helped reverse severe hair loss in patients.

Glehnia littoralis and Andrographis paniculata extracts can significantly boost hair growth.

Blocking IL-12/IL-23 does not help with hair loss in alopecia areata for mice or humans.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.

Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.

Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.

The document concludes that scalp conditions have various causes and can present in many different ways.

Topical treatments helped a child with Down syndrome and severe hair loss regrow most of his hair.

Laser therapy might help regrow hair in alopecia totalis better than steroids alone.

Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.

Alopecia areata is an autoimmune disease causing patchy hair loss, often with other autoimmune disorders, but its exact causes are unknown.

Both vitiligo and alopecia areata involve an immune response triggered by stress and specific genes, with treatments targeting this pathway showing potential.

Tissue-resident memory T cells can protect against infections and cancer but may also contribute to autoimmune diseases.

Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.

Apremilast was not effective in treating moderate-to-severe alopecia areata.

Tofacitinib and oral minoxidil together effectively regrow hair in severe alopecia areata patients.

A new mix of anthralin and calcipotriene might help treat severe hair loss.

Increasing Treg cells in the skin does not cure hair loss from alopecia areata in mice.

The combination therapy was effective and well-tolerated, especially in young patients.

Using minoxidil and tofacitinib together can effectively treat severe hair loss.